Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Health Care M&A Deals, Week Ending December 6, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Baker Bros. Advisors LP Royalties on KSI-301 $225,000,000 Astellas Pharma Inc. Audentes Therapeutics, Inc. $3,000,000,000 eHealth Acquirer Target Price Oasis Group Niche Health N/A Waystar Recondo Technology N/A Dedalus Group Agfa-Gevaert’s... Read More »
Big Pharma Is Back in the Headlines
It looks like some big pharma companies want to get their holiday shopping done early this year. Two transactions with values north of $1 billion were announced in late November, stimulating a sector that’s been relatively quiet the past few months. The first might not come as a surprise since it’s been circling the rumor mill for some time. Novartis AG (NYSE: NVS) announced the acquisition of The Medicines Company (NASDAQ: MDCO) for $9.7 billion, or $85 per share. The deal value is comprised of a 24% premium over MDCO’s November 22, 2019 closing price of $68.55, as well as the company’s outstanding stock options and convertible debt. MDCO is focused on treating... Read More »
Accent Acquired by HMS Holdings Corp.
After making a string of digital health deals over the past few years, HMS Holdings Corp. (NASDAQ: HMSY) has now expanded into the managed care sector. In the last week of November, the company announced its acquisition of Accent from Intrado Corporation for $155 million. The target company is a payment accuracy and cost containment business. Accent’s healthcare payer clients include large commercial health plans, Blue Cross and Blue Shield plans, provider-sponsored health plans, Medicare Advantage plans, third-party administrators and self-insured employer groups. Its offerings include comprehensive prospective and retrospective claims accuracy solutions, which incorporate cost avoidance... Read More »
Health Care M&A Deals, Week Ending November 29, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Enochian Biosciences Inc. License for hepatitis B virus treatment N/A JanOne Inc. Exclusive license for TV1001SR N/A Home Health Care & Hospice Acquirer Target Price AMEDISYS, INC. Asana Hospice... Read More »
DFW Home Health Adds Fourth Home Health Agency
DFW Home Health, a Dallas-based home health provider jointly owned by LHC Group (NASDAQ: LHCG), Texas Health Resources and Methodist Health System, acquired Healthcare Resources, a home health provider serving patients and families in Arlington, Texas. Healthcare Resources offers skilled nursing, physical therapy, occupational therapy, speech therapy, medical social services, home health aides and other specialty services. Its name will be changed to DFW Home Health Arlington. This deal marks the expansion of DFW Home Health’s footprint to four locations across the Dallas-Fort Worth MSA, including in Dallas, Fort Worth and Denton, Texas. DFW provides in-home healthcare services for 25... Read More »
Hospice Deals Heat Up
It’s been a busy year in the Home Health & Hospice sector. Deal volume is poised to surpass the record 85 transactions announced in 2018. Through late November, 79 deals are in our DealSearchOnline database and more are expected before year-end. Home health agencies account for the bulk of the transactions every year, making up 72% in both 2015 and 2016, for example. In the past two years, however, hospice companies have seen a surge in investor interest. In 2018, hospice companies accounted for 33% of the 85 deals in the sector. Through the end of November 2019, they make up 38% of the sector’s deal count. Valuations are often described as “frothy” for home... Read More »
Health Care M&A Deals, Week Ending November 22, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Aerie Pharmaceuticals, Inc. Avizorex Pharma, S.L $10,000,000 Advent International Bharat Serums and Vaccines Limited N/A Alkermes, Inc. Rodin Therapeutics, Inc. $100,000,000 Appili Therapeutics Inc. Novel antifungal drug ATI-2307 N/A eHealth... Read More »
Lumenis Finally Finds a Buyer
After a four-year partnership, XIO Group has finally sold Lumenis. CVC Capital Partners and FountainVest Partners came incredibly close to purchasing the medical device firm late last year for an estimated $950 million, according to reports in Calcalist, but the deal was never finalized. Fast forward to the present day, and Baring Private Equity Asia (BPEA) has emerged as the buyer, spending $1 billion for the Israeli firm. Lumenis provides specialty minimally invasive medical devices in the fields of aesthetics, urology, ophthalmology, ENT, and gynecology. The company has a presence in more than 100 countries. XIO Group acquired Lumenis in 2015 for $510 million, or $14 a share, when the... Read More »
LGC Gets New Owners After Multi-Billion Deal
Cinven and Astorg have joined forces to purchase LGC Group from KKR (NYSE: KKR). The two global private equity firms spent $3.88 billion (£3 billion) for the firm, according to sources cited in Private Equity News. LGC provides a range of measurement tools, proficiency testing schemes, supply chain assurance standards, and specialty genomics reagents to the life sciences industry. According to our Deal Search Online database, this is the largest deal in the Laboratories, MRI and Dialysis sector, based on disclosed prices in 2019. This deal ends a four-year partnership that started in December 2015 when KKR acquired LGC for $989 million. At the time, LGC was a portfolio company of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
